Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02533310
Other study ID # VIMSE
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2015
Est. completion date April 30, 2019

Study information

Verified date February 2021
Source Stockholm University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to examine the efficacy of virtual reality exposure therapy as a treatment for specific phobia (spiders). A gamified virtual reality simulation of one-session therapy (VR-OST) will be compared to the gold-standard treatment in the form of traditional one-session phobia treatment (OST) using in-vivo stimuli. This study was powered to detect a non-inferiority margin of a 2-point difference between groups.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date April 30, 2019
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Score of 10 or less in Behavioral Approach Test - Individual meeting DSM-5 criteria according to interview for primary diagnosis of specific phobia, spider - Swedish residency - Fluent in Swedish Exclusion Criteria: - Ongoing psychotherapy - Ongoing psychotropic medication (unless stabilized for three months) - Indication of suicidal ideation, as assessed by item 9 of the PHQ-9 - Meets criteria for alcohol or substance use disorder - Meets criteria for serious mental disorder, such as bipolar disorder, schizophrenia or psychosis - Balance and/or eyesight problems (such as lack of stereoscopic vision) that could interfere with VR treatment

Study Design


Related Conditions & MeSH terms


Intervention

Other:
OST treatment with in-vivo spiders
Subjects are exposed to phobic stimuli with the aid of a trained psychotherapist during a session of maximum 3 hrs duration. The intensity of exposure is increased in four sequential steps, 1. learning to catch a spider with a glass and paper, 2. touching a spider, 3. letting a spider walk on your hand, 4. letting a spider walk on your body. These stages repeat with increasingly larger spiders. The goal of therapy is not absolute symptom reduction but sufficient reduction to allow the individual to expose themselves in everyday situations.
VR-OST treatment with virtual spiders
The VR-OST treatment introduces a virtual gamified version of OST treatment using a modern virtual reality headset. Individuals advance themselves through increasing levels of exposure intensity with the assistance of an automated virtual therapist.

Locations

Country Name City State
Sweden Department of Psychology Stockholm

Sponsors (1)

Lead Sponsor Collaborator
Stockholm University

Country where clinical trial is conducted

Sweden, 

References & Publications (1)

Miloff A, Lindner P, Dafgård P, Deak S, Garke M, Hamilton W, Heinsoo J, Kristoffersson G, Rafi J, Sindemark K, Sjölund J, Zenger M, Reuterskiöld L, Andersson G, Carlbring P. Automated virtual reality exposure therapy for spider phobia vs. in-vivo one-sess — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Behavioral Approach Test (BAT) The BAT consists of 13 approach steps measuring intensity of phobia symptoms, from approaching a few metres from to holding a spider. Change from baseline on BAT (1 week)
Primary Behavioral Approach Test (BAT) The BAT consists of 13 approach steps measuring intensity of phobia symptoms, from approaching a few metres from to holding a spider. Change from baseline on BAT (12 week)
Primary Behavioral Approach Test (BAT) The BAT consists of 13 approach steps measuring intensity of phobia symptoms, from approaching a few metres from to holding a spider. Change from baseline on BAT (52 week)
Secondary Spider Phobia Questionnaire 31 (SPQ-31) SPQ-31 features 31 spider-focused scenarios which must be answered by a yes/no response, with ascending scores indicative of increased degree of arachnophobia. Change from baseline on SPQ-31 (1 week)
Secondary Spider Phobia Questionnaire 31 (SPQ-31) SPQ-31 features 31 spider-focused scenarios which must be answered by a yes/no response, with ascending scores indicative of increased degree of arachnophobia. Change from baseline on SPQ-31 (12 week)
Secondary Spider Phobia Questionnaire 31 (SPQ-31) SPQ-31 features 31 spider-focused scenarios which must be answered by a yes/no response, with ascending scores indicative of increased degree of arachnophobia. Change from baseline on SPQ-31 (52 week)
Secondary Spider Phobia Questionnaire 31 (SPQ-31) SPQ-31 features 31 spider-focused scenarios which must be answered by a yes/no response, with ascending scores indicative of increased degree of arachnophobia. Change from baseline on SPQ-31 (3 year)
Secondary Fear of Spiders Questionnaire 18 (FSQ-18) FSQ-18 features 18 questions about fear and avoidance of spiders. Change from baseline in FSQ-18 (1 week)
Secondary Fear of Spiders Questionnaire 18 (FSQ-18) FSQ-18 features 18 questions about fear and avoidance of spiders. Change from baseline in FSQ-18 (12 week)
Secondary Fear of Spiders Questionnaire 18 (FSQ-18) FSQ-18 features 18 questions about fear and avoidance of spiders. Change from baseline in FSQ-18 (52 week)
Secondary Fear of Spiders Questionnaire 18 (FSQ-18) FSQ-18 features 18 questions about fear and avoidance of spiders. Change from baseline in FSQ-18 (3 year)
Secondary Generalized Anxiety Disorder Assessment 7 (GAD-7) GAD-7 features seven items for assessing anxiety and screening for generalized anxiety disorder. Change from baseline in GAD-7 (1 week)
Secondary Generalized Anxiety Disorder Assessment 7 (GAD-7) GAD-7 features seven items for assessing anxiety and screening for generalized anxiety disorder. Change from baseline in GAD-7 (12 week)
Secondary Generalized Anxiety Disorder Assessment 7 (GAD-7) GAD-7 features seven items for assessing anxiety and screening for generalized anxiety disorder. Change from baseline in GAD-7 (52 week)
Secondary Generalized Anxiety Disorder Assessment 7 (GAD-7) GAD-7 features seven items for assessing anxiety and screening for generalized anxiety disorder. Change from baseline in GAD-7 (3 year)
Secondary Patient Health Questionnaire 9 (PHQ-9) PHQ-9 features nine items for assessing depression in a clinical context and screening of depression in the general population. Change from baseline in PHQ-9 (1 week)
Secondary Patient Health Questionnaire 9 (PHQ-9) PHQ-9 features nine items for assessing depression in a clinical context and screening of depression in the general population. Change from baseline in PHQ-9 (12 week)
Secondary Patient Health Questionnaire 9 (PHQ-9) PHQ-9 features nine items for assessing depression in a clinical context and screening of depression in the general population. Change from baseline in PHQ-9 (52 week)
Secondary Patient Health Questionnaire 9 (PHQ-9) PHQ-9 features nine items for assessing depression in a clinical context and screening of depression in the general population. Change from baseline in PHQ-9 (3 year)
Secondary Brunnsviken Brief Quality of Life Scale (BBQ) BBQ features 12 items concerning 6 areas of life rated on importance and satisfaction. Change from baseline in BBQ (1 week)
Secondary Brunnsviken Brief Quality of Life Scale (BBQ) BBQ features 12 items concerning 6 areas of life rated on importance and satisfaction. Change from baseline in BBQ (12 week)
Secondary Brunnsviken Brief Quality of Life Scale (BBQ) BBQ features 12 items concerning 6 areas of life rated on importance and satisfaction. Change from baseline in BBQ (52 week)
Secondary Brunnsviken Brief Quality of Life Scale (BBQ) BBQ features 12 items concerning 6 areas of life rated on importance and satisfaction. Change from baseline in BBQ (3 year)
Secondary Diagnostic criteria for specific phobia according to interview (DSM-5) Change from baseline for specific phobia (DSM-5) (12 weeks)
Secondary Diagnostic criteria for specific phobia according to interview (DSM-5) Change from baseline for specific phobia (DSM-5) (52 weeks)
Secondary Diagnostic criteria for specific phobia according to interview (DSM-5) Change from baseline for specific phobia (DSM-5) (3 years)
See also
  Status Clinical Trial Phase
Completed NCT02622087 - The Impact of Sex Hormones on One-session Treatment for Spider Phobia in Women N/A
Completed NCT02789813 - Influence of Valproic Acid on Extinction-based Therapy in Patients With Fear of Spiders. Phase 2